ABUS (Arbutus Biopharma Corporation Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ABUS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-10 | Robert A Beardsley | Director | A | — | — |
| 2026-06-10 | Roger Sawhney | Director | A | — | — |
| 2026-02-02 | Lindsay Androski | President and CEO | A | — | — |
| 2026-02-02 | Tuan Nguyen | Chief Financial Officer | A | — | — |
| 2025-08-06 | Roger Sawhney | Director | A | — | — |
| 2025-04-01 | Tuan Nguyen | Chief Financial Officer | A | — | — |
| 2025-03-31 | Tuan Nguyen | Chief Financial Officer | A | — | — |
| 2025-03-20 | Anuj Hasija | Director | A | — | — |
| 2025-03-20 | Robert A Beardsley | Director | A | — | — |
| 2025-03-20 | Lindsay Androski | President and CEO | A | — | — |
| 2025-02-19 | Karen Sims | Chief Medical Officer | A | — | — |
| 2025-02-19 | Michael J. McElhaugh | Interim President & CEO | A | — | — |
| 2025-02-19 | DAVID C HASTINGS | Chief Financial Officer | A | — | — |
| 2025-02-19 | J. Christopher Naftzger | General Counsel and CCO | A | — | — |
| 2025-02-05 | J. Christopher Naftzger | General Counsel and CCO | Sell | — | — |
| 2025-02-05 | DAVID C HASTINGS | Chief Financial Officer | Sell | — | — |
| 2025-02-05 | Michael J. McElhaugh | Interim President & CEO | Sell | — | — |
| 2025-02-05 | Karen Sims | Chief Medical Officer | Sell | — | — |
| 2024-08-16 | KEITH S MANCHESTER | Director | MIXED | — | — |
| 2024-05-24 | KEITH S MANCHESTER | Director | A | — | — |
| 2024-05-24 | Frank Torti | Director | A | — | — |
| 2024-05-24 | Melissa Rewolinski | Director | A | — | — |
| 2024-05-24 | James R Meyers | Director | A | — | — |
| 2024-05-24 | DANIEL D BURGESS | Director | A | — | — |
| 2024-05-24 | RICHARD C JR HENRIQUES | Director | A | — | — |
| 2024-02-05 | DAVID C HASTINGS | Chief Financial Officer | MIXED | — | — |
| 2024-02-05 | Michael J. McElhaugh | Interim President & CEO | MIXED | — | — |
| 2024-02-05 | Michael J. Sofia | Chief Scientific Officer | MIXED | — | — |
| 2024-02-05 | Karen Sims | Chief Medical Officer | MIXED | — | — |
| 2024-02-05 | J. Christopher Naftzger | General Counsel and CCO | A | — | — |
| 2023-07-13 | Melissa Rewolinski | Director | A | — | — |
| 2023-07-12 | J. Christopher Naftzger | General Counsel and CCO | A | — | — |
| 2023-07-12 | Karen Sims | Chief Medical Officer | A | — | — |
| 2023-05-26 | James R Meyers | Director | A | — | — |
| 2023-05-26 | DANIEL D BURGESS | Director | A | — | — |
| 2023-05-26 | RICHARD C JR HENRIQUES | Director | A | — | — |
| 2023-05-26 | KEITH S MANCHESTER | Director | A | — | — |
| 2023-05-26 | Frank Torti | Director | A | — | — |
| 2023-02-03 | William H. Collier | President and CEO | A | — | — |
| 2023-02-03 | DAVID C HASTINGS | Chief Financial Officer | A | — | — |
| 2023-02-03 | Michael J. Sofia | Chief Scientific Officer | A | — | — |
| 2023-02-03 | Elizabeth Howard | EVP, GC, Compliance | A | — | — |
| 2023-02-03 | Michael J. McElhaugh | Chief Business Officer | A | — | — |
| 2022-05-26 | RICHARD C JR HENRIQUES | Director | A | — | — |
| 2022-05-26 | Frank Torti | Director | A | — | — |
| 2022-05-26 | James R Meyers | Director | A | — | — |
| 2022-05-26 | DANIEL D BURGESS | Director | A | — | — |
| 2022-05-26 | Tram Tran | Director | A | — | — |
| 2022-05-26 | KEITH S MANCHESTER | Director | A | — | — |
| 2022-01-20 | DAVID C HASTINGS | Chief Financial Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 38,847,462 | — |
| — | Chief Scientific Officer | 1,662,265 | — |
| — | Interim President & CEO | 1,658,003 | — |
| — | President and CEO | 341,396 | — |
| — | Chief Financial Officer | 249,824 | — |
| — | President and CEO | 216,500 | — |
| — | Chief Medical Officer | 155,494 | — |
| — | General Counsel and CCO | 140,544 | — |
| — | EVP, GC, Compliance | 86,024 | — |
| — | Chief Financial Officer | 73,500 | — |
| — | Director | 46,069 | — |
| — | Managing Director | 42,097 | — |
| — | President and CEO | 28,000 | — |
| — | Director | 1,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ABUS quote page; the site-wide leaderboard is on the insider transactions hub.